Study was cancelled due to reclassification of study design. No subjects enrolled in the study.

This study aims to characterize the Portuguese population of patients with moderate-to-severe UC receiving advanced therapies, by describing clinical and sociodemographic characteristics, and remission outcomes . The clinical, biochemical, endoscopic, and histological outcomes will also be described, as well as frequency of selected EIM, comorbidities and the uptake of preventive care measures and hospitalizations .

Inclusion Criteria:

• Aged at least 18 years old
• Diagnosed with Ulcerative Colitis, confirmed by a gastroenterologist
• Treated with anti-TNF or anti-integrin or JAK inhibitors drugs for at least 16 weeks
• Followed at one of the participating centers when initiating and during the current treatment
• Signed informed consent

Exclusion Criteria:

• Treated with anti-TNF or anti-integrin or JAK inhibitors drugs at induction phase
• Enrolled in randomized clinical trials or other experimental studies in the last 12 months prior to initiation of advanced therapy

Patients followed at Portuguese gastroenterology services, presenting moderate-to-severe Ulcerative Colitis and receiving advanced therapies (i.e., anti-TNF or anti-integrin or JAK inhibitors drugs) for at least 16 weeks.

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.